These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 18163888)
21. Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles. Yu HK; Kim JS; Lee HJ; Ahn JH; Lee SK; Hong SW; Yoon Y Cancer Res; 2004 Oct; 64(19):7092-8. PubMed ID: 15466205 [TBL] [Abstract][Full Text] [Related]
22. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Hu J; Dong A; Fernandez-Ruiz V; Shan J; Kawa M; Martínez-Ansó E; Prieto J; Qian C Cancer Res; 2009 Sep; 69(17):6951-9. PubMed ID: 19690140 [TBL] [Abstract][Full Text] [Related]
23. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Sakamoto K; Maeda S; Hikiba Y; Nakagawa H; Hayakawa Y; Shibata W; Yanai A; Ogura K; Omata M Clin Cancer Res; 2009 Apr; 15(7):2248-58. PubMed ID: 19276252 [TBL] [Abstract][Full Text] [Related]
24. Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice. Galaup A; Magnon C; Rouffiac V; Opolon P; Opolon D; Lassau N; Tursz T; Perricaudet M; Griscelli F Gene Ther; 2005 May; 12(10):831-42. PubMed ID: 15789064 [TBL] [Abstract][Full Text] [Related]
25. Gene transfer of kringle 1-5 suppresses tumor development and improves prognosis of mice with hepatocellular carcinoma. Torimura T; Ueno T; Kin M; Taniguchi E; Nakamura T; Inoue K; Sakata R; Hashimoto O; Sakamoto M; Ohira H; Kumashiro R; Sata M; Yano H; Kojiro M; Veitonmaki N; Cao Y Gastroenterology; 2006 Apr; 130(4):1301-10. PubMed ID: 16618420 [TBL] [Abstract][Full Text] [Related]
26. [Cloning and antitumor activity of angiogenesis inhibitor HIAF-1]. Guo W; Yang Z; Liu J Zhonghua Zhong Liu Za Zhi; 2000 Jan; 22(1):19-21. PubMed ID: 11776588 [TBL] [Abstract][Full Text] [Related]
27. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. Dienst A; Grunow A; Unruh M; Rabausch B; Nör JE; Fries JW; Gottstein C J Natl Cancer Inst; 2005 May; 97(10):733-47. PubMed ID: 15900043 [TBL] [Abstract][Full Text] [Related]
28. Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity. Lee SB; Oh HK; Kim HK; Joe YA Protein Expr Purif; 2006 Nov; 50(1):1-8. PubMed ID: 16854593 [TBL] [Abstract][Full Text] [Related]
29. The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF. Kim JH; Kim JC; Shin SH; Chang SI; Lee HS; Chung SI Exp Mol Med; 1999 Dec; 31(4):203-9. PubMed ID: 10630375 [TBL] [Abstract][Full Text] [Related]
30. Immunoglobulin Fc domain fusion to apolipoprotein(a) kringle V significantly prolongs plasma half-life without affecting its anti-angiogenic activity. Yu HK; Lee HJ; Ahn JH; Lim IH; Moon JH; Yoon Y; Yi LS; Kim SJ; Kim JS Protein Eng Des Sel; 2013 Jun; 26(6):425-32. PubMed ID: 23571426 [TBL] [Abstract][Full Text] [Related]
31. Brain hyaluronan binding protein inhibits tumor growth. Gao F; Cao ML; Wang L Chin Med J (Engl); 2004 Jul; 117(7):1072-8. PubMed ID: 15265385 [TBL] [Abstract][Full Text] [Related]
32. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496 [TBL] [Abstract][Full Text] [Related]
33. High level expression of kringle 5 fragment of plasminogen in Pichia pastoris. Zhou Y; Zheng Q; Gao J; Gu J Biotechnol Lett; 2005 Feb; 27(3):167-71. PubMed ID: 15717125 [TBL] [Abstract][Full Text] [Related]
34. Potent anti-tumor and prolonged survival effects of E. coli-derived non-glycosylated kringle domain of tissue-type plasminogen activator. Kang BH; Shim BS; Lee SY; Lee SK; Hong YK; Joe YA Int J Oncol; 2006 Feb; 28(2):361-7. PubMed ID: 16391790 [TBL] [Abstract][Full Text] [Related]
35. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol. Shibata A; Nakagawa K; Sookwong P; Tsuzuki T; Oikawa S; Miyazawa T Biochem Pharmacol; 2008 Aug; 76(3):330-9. PubMed ID: 18599020 [TBL] [Abstract][Full Text] [Related]
36. Targeting matrix metalloproteinases and endothelial cells with a fusion peptide against tumor. Zou Y; Chen Y; Jiang Y; Gao J; Gu J Cancer Res; 2007 Aug; 67(15):7295-300. PubMed ID: 17671198 [TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system. Liu L; Boffa MB; Koschinsky ML PLoS One; 2013; 8(1):e52287. PubMed ID: 23326327 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine. Ono M; Kawahara N; Goto D; Wakabayashi Y; Ushiro S; Yoshida S; Izumi H; Kuwano M; Sato Y Cancer Res; 1996 Apr; 56(7):1512-6. PubMed ID: 8603395 [TBL] [Abstract][Full Text] [Related]
39. Anti-angiogenesis and anti-tumor effects of AdNT4-anginex. Dong DF; Li EX; Wang JB; Wu YY; Shi F; Guo JJ; Wu Y; Liu JP; Liu SX; Yang GX Cancer Lett; 2009 Nov; 285(2):218-24. PubMed ID: 19540664 [TBL] [Abstract][Full Text] [Related]
40. A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: expression, purification, and characterization. Smirnoff P; Roiz L; Angelkovitch B; Schwartz B; Shoseyov O Cancer; 2006 Dec; 107(12):2760-9. PubMed ID: 17109444 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]